Proteinqure Inc. has closed an $11 million series A financing round to support the initiation of the company’s first clinical trial for PQ-203, a first-in-class peptide-drug conjugate for triple-negative breast cancer (TNBC). The funds will also be used to advance additional pipeline programs in neurology and nephrology.
Monte Rosa Therapeutics Inc. has divulged molecular glues as cyclin-dependent kinase 2 (CDK2) degradation inducers reported to be useful for the treatment of cancer and amyloidosis.
University of Michigan has disclosed prodrugs of stimulator of interferon genes protein (STING; TMEM173) agonists reported to be useful for the treatment of cancer, autoimmune disease, inflammatory disorder and infections.
Cell division cycle 20 homolog (CDC20) is a key regulatory protein involved in mitotic progression. Aberrant overexpression of CDC20 has been implicated in tumorigenesis and is associated with poor prognosis in several cancers, including triple-negative breast cancer.
Hepatocellular carcinoma (HCC) is a fatal cancer and the third cause of cancer-related deaths worldwide. Current therapies have focused on CAR T cells for treating HCC. Glypican-3 (GPC3) is a membrane protein that is overexpressed in HCC but not in healthy adult liver tissue, thus becoming a promising therapeutic target for HCC management.
Cholangiocarcinoma is a rare cancer that arises from the intrahepatic biliary epithelium or extrahepatic bile ducts. Apart from genetic mutations, epigenetic changes are also contributing to cancer development, making DNA methylation and histone modification focus for cancer research.
To overcome the current limitations of antitumor immunotherapy, in situ vaccine platforms based on intelligent microbes are gaining increased attention due to their ability to sustainably deliver drugs locally without causing severe systemic risks.
Neuroblastoma is a pediatric solid tumor characterized by dysregulation of the CDK-RB-E2F axis, leading to elevated E2F activity, uncontrolled progression through the G1/S transition and an aggressive tumor phenotype. Researchers from Circle Pharma Inc. and collaborators presented preclinical data on CID-078, a first-in-class oral macrocycle with dual cyclin A and B RxL inhibitory activity, in models of neuroblastoma.
Phosphoinositide signaling pathways have been implicated in the metabolic alterations associated with various human diseases, including breast cancer. The phosphatidylinositol-5-phosphate 4-kinase (PIP4K) family catalyzes the phosphorylation of phosphatidylinositol-5-phosphate (PI5P) to produce phosphatidylinositol-4,5-bisphosphate (PI(4,5)P2), a lipid that regulates signaling pathways associated with cancer cell growth and metastasis.
RSS
